United Therapeutics reported record third-quarter revenue, including record Tyvaso sales, while the stock rose 1.2%—a roughly flat reaction. The transcript highlights commercial momentum and a broad development pipeline, but provides limited detail on forward guidance or financial outlook.
- Total revenue reached a record **$833 million**; Tyvaso revenue also set a record at **$504 million**.
- Management attributed Tyvaso growth to underlying demand, including starts, referrals, increased dosing, and physician engagement, and said it sees room for further growth.
- The company cited **14 programs in development** across cardiopulmonary and respiratory medicine, targeting patient populations totaling approximately **1 million in the U.S.** across IPF, PPF, and PH-COPD.
- Management pointed to intellectual property protections extending into the 2040s for many portfolio assets, alongside commercialization and manufacturing capabilities.
- The provided transcript excerpt does not include detailed financial guidance or a quantified outlook.
Community Discussion